Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DUT | P33316 | 11/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957852 | 0.89 | DUT (0.55) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL4348697 | 0.87 | L3MBTL1 (0.59) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL912535 | 0.87 | DUT (0.55) | L3MBTL1DUTCRBN | |
| SCHEMBL2215255 | 0.85 | DUT (0.54) | L3MBTL1DUT | |
| SCHEMBL6102943 | 0.85 | CRBN (0.56) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL3235869 | 0.84 | L3MBTL1 (0.53) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL14861415 | 0.82 | L3MBTL1 (0.54) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL31592762 | 0.81 | L3MBTL1 (0.58) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL2983407 | 0.80 | ALDH1A1 (0.57) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL16632410 | 0.80 | L3MBTL1 (0.53) | L3MBTL1DUTCRBNPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605545-A1 | DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES | F. Hoffmann-La Roche AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120051575-A | Detection of modified nucleobases in nucleic acid samples | 豪夫迈·罗氏有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024083982-A1 | DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-04-25 | — | — | WO | claimed |
| EP-4605545-A1 | DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES | F. Hoffmann-La Roche AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| CN-120051575-A | Detection of modified nucleobases in nucleic acid samples | 豪夫迈·罗氏有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117957328-A | Polynucleotide and use thereof | 斯特兰德生物科技公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024083982-A1 | DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| CN-111378162-A | Energy absorption method based on dynamic polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| US-7777024-B2 | Process for preparing a pentopyranosyl nucleic acid conjugate | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | SANOFI-AVENTIS S.A. (FR) | 2009-09-03 | — | — | US | disclosed |
| EP-1034180-A2 | LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | Nanogen Recognomics GmbH (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-1019423-A2 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | Nanogen Recognomics GmbH (DE) | 2000-07-19 | — | — | EP | disclosed |
| EP-1017704-A2 | USE OF A PENTOPYRANOSYL NUCLEOSIDE CONTAINING CONJUGATE FOR PRODUCING AN ARRAY | Nanogen Recognomics GmbH (DE) | 2000-07-12 | — | — | EP | disclosed |
| EP-1017703-A2 | PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | Nanogen Recognomics GmbH (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999052923-A2 | METHOD FOR THE PRODUCTION OF PENTOPYRANOSYL NUCLEOSIDES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999015540-A2 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015542-A2 | LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015539-A2 | PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015541-A2 | USE OF A PENTOPYRANOSYL NUCLEOSIDE FOR PRODUCING AN ELECTRONIC COMPONENT, AND CONJUGATES OF SAID PENTOPYRANOSYL NUCLEOSIDE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | RNGTT, NT5C3B, FUT6 | L3MBTL1 1933/4885DUT 11/4885CRBN 1660/4885 |
| US-12018260-B2 | Tunable Reversir™ compounds | SNRPE, PLK1, LDLR | L3MBTL1 2390/4885DUT 228/4885CRBN 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.